|
|
Article: Bristol-Myers Squibb Acquires Novel Oncology Drug From Manitoba Cancer Treatment & Research Foundation
- Article from:
- PR Newswire
- Article date:
- September 5, 1996
CopyrightCOPYRIGHT 1996 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DPPE a Promising Therapy for Prostate and Breast Cancers
PRINCETON, N.J., MONTREAL, and WINNIPEG, Manitoba, Sept. 5 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY), the Manitoba Cancer Treatment and Research Foundation (MCTRF), and the University of Manitoba, Canada, announced today a license agreement under which Bristol-Myers Squibb will develop and market DPPE, a novel treatment for cancer. In preclinical tests and in clinical trials conducted at MCTRF in patients with prostate and breast cancer, DPPE appears to enhance the cytotoxic effects of chemotherapy with no additive unwanted side effects.
Under the terms of the agreement, ...